List of patients on Originator/Innovator Biologics for transition to Biosimilars

Last Updated May 9, 2023

The Ontario government is expanding its drug coverage policy to further promote the use of biosimilars funded through the Ontario Drug Benefit (ODB) program. As of March 31, 2023, ODB patients who are currently on select originator biologics must transition to a Health Canada approved biosimilar equivalent by December 29, 2023 to maintain coverage under ODB, unless they have an approved medical exemption.

For more information, please refer to the Ministry of Health INFOBulletin.

On March 10, the Ministry of Health faxed prescribers a list of patients impacted by the new biosimilars policy; however, the fax did not include patients on Humalog®, Lantus® or NovoRapid®.

To assist clinicians, OntarioMD has developed queries for Accuro® EMR, OSCAR Pro, and TELUS PSS to identify your patients who have been prescribed products affected by the new biosimilars policy. You can easily download, import and run these queries to produce a report of patients on any of the following products:

  • Copaxone®
  • Enbrel®
  • Humalog®
  • Humira®
  • Lantus®
  • NovoRapid®
  • Remicade®
  • Rituxan®

Your next step is to check whether these patients have one or more biologics that are currently covered by ODB. To do this, you can access the provincial DHDR (Digital Health Drug Repository) directly from your EMR. You launch the DHDR from the patient’s chart in your EMR to view publicly funded drugs dispensed in Ontario and paid by the Ontario Drug Benefit (ODB) program. These include the ones listed in the Formulary or approved through the Exceptional Access Program (EAP). Alternatively, you can manually cross-check the patient list generated by the query with DHDR via the Connecting Ontario portal.

Get more information or sign up for DHDR.

TELUS PSS Search for patients on originator biologics.
Originator/Innovator Biologics for transition to Biosimilar
Note this search will look for patients with current active medications of Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade®, and Rituxan®.

OSCAR Pro Report by Template for patients on originator biologics.
List of patients on Originator/Innovator Biologics for transition to Biosimilars
Note this search will look for patients with current active medications of Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade®, and Rituxan®.

QHR Accuro Query for patients on originator biologics published on Accuro Definition Publisher.
List of patients on Originator/Innovator Biologics for transition to Biosimilars
Note this search will look for patients with current active medications of Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade®, and Rituxan®.

NEED HELP DOWNLOADING OR IMPORTING TOOLS TO YOUR EMR?
CLICK HERE TO REVIEW HOW-TO RESOURCES.